BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 25223100)

  • 1. Ups and downs at ASCO 2014.
    Adams KT
    Manag Care; 2014 Aug; 23(8):50-2. PubMed ID: 25223100
    [No Abstract]   [Full Text] [Related]  

  • 2. The most important news at ASCO 2009.
    DeVita VT
    Nat Rev Clin Oncol; 2009 Jul; 6(7):371. PubMed ID: 19561629
    [No Abstract]   [Full Text] [Related]  

  • 3. ASCO report highlights challenges in delivering high-quality care.
    Printz C
    Cancer; 2015 Jul; 121(14):2292-3. PubMed ID: 26132387
    [No Abstract]   [Full Text] [Related]  

  • 4. A window into new drug development for urologic oncology. Part I: How bench-to-bedside research can result in approval.
    Haas GP; Scher HI
    Urol Oncol; 2015 Mar; 33(3):115. PubMed ID: 25620153
    [No Abstract]   [Full Text] [Related]  

  • 5. ASCO in the 21st century: challenges and opportunities--ASCO presidential address 2005.
    Johnson DH
    J Clin Oncol; 2006 May; 24(13):1967-71. PubMed ID: 16648494
    [No Abstract]   [Full Text] [Related]  

  • 6. Oncology update.
    Smart M
    Oncol Nurs Forum; 2011 Jul; 38(4):485-6. PubMed ID: 21708539
    [No Abstract]   [Full Text] [Related]  

  • 7. ASCO, AACR issue joint response to proposed FDA tobacco rule.
    Printz C
    Cancer; 2014 Dec; 120(24):3848-9. PubMed ID: 25474226
    [No Abstract]   [Full Text] [Related]  

  • 8. 2015 ASCO Annual Meeting.
    Coburn C
    Lancet Oncol; 2015 Jul; 16(7):755-6. PubMed ID: 26062778
    [No Abstract]   [Full Text] [Related]  

  • 9. Better prioritization may speed approval of adjuvant therapies in breast cancer.
    Tuma RS
    J Natl Cancer Inst; 2008 Jun; 100(12):842-4. PubMed ID: 18544735
    [No Abstract]   [Full Text] [Related]  

  • 10. An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical Trials.
    Kumar H; Fojo T; Mailankody S
    JAMA Oncol; 2016 Sep; 2(9):1238-40. PubMed ID: 27281466
    [No Abstract]   [Full Text] [Related]  

  • 11. ASCO 2011: broadening the horizons of cancer research.
    Crane K
    J Natl Cancer Inst; 2011 Jul; 103(13):999-1001. PubMed ID: 21693729
    [No Abstract]   [Full Text] [Related]  

  • 12. [American Society of Clinical Oncology (ASCO) 2011 essential data: the editorial board of the Bulletin du Cancer point of view].
    Vignot S; Bay JO; Blay JY; Gonçalves A; Massard C; Thariat J; Wislez M; André T
    Bull Cancer; 2011 Dec; 98(12):1509-23. PubMed ID: 22182714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R
    J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
    [No Abstract]   [Full Text] [Related]  

  • 14. International Conference on Harmonisation; guidance on specifications: test procedures and acceptance criteria for biotechnological/biological products. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1999 Aug; 64(159):44928-35. PubMed ID: 12356094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International Conference on Harmonisation; guidance on quality of biotechnological/biological products: derivation and characterization of cell substrates used for production of biotechnological/biological products; availability. Notice. Food and Drug Administration, HHS.
    Fed Regist; 1998 Sep; 63(182):50244-9. PubMed ID: 12269373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Issues in oncology management. Introduction.
    Manag Care; 2007 Mar; 16(3 Suppl 4):2-4. PubMed ID: 18575213
    [No Abstract]   [Full Text] [Related]  

  • 17. Neuro-oncology: a selected review of ASCO 2011 abstracts.
    Chamberlain MC
    Expert Rev Neurother; 2011 Oct; 11(10):1371-7. PubMed ID: 21955193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Food and drug administration expanded access to treatment: implications for oncology patients.
    Freedman RS; Markman M
    Cancer; 2007 Jun; 109(11):2157-60. PubMed ID: 17450587
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacogenetics and other molecular targets in the management of pancreatic adenocarcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
    Merika E; Syrigos KN; Saif MW
    JOP; 2010 Jul; 11(4):328-30. PubMed ID: 20601804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy sensitivity and response assays: are the ASCO guidelines for clinical trial design too restrictive?
    Wieand HS
    J Clin Oncol; 2005 May; 23(15):3643-4; author reply 3646-8. PubMed ID: 15908687
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.